Group items tagged

Prostate cancer survival is dependent on season of diagnosis

Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC.

Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients with solid tumors with neuroendocrine features. C. M. Rudin, D. Lansey, K. D. Burroughs, L. M. Hales, J. R. Neefe, P. S. Reddy and P. L. Hallenbeck Johns Hopkins Univ, Baltimore, MD; Neotropix, Inc., Malvern, PA. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 18014 © 2007 American Society of Clinical Oncology. Conclusions: NTX-010 is a novel first-in-class anticancer virus with selective tropism for tumors with neuroendocrine features. This is the first anticancer virus given intravenously with documented selective intratumoral infection and replication. Administration was well tolerated. Safety data and viral kinetics will be presented.

Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity. Frank MB, Yang Q, Osban J, Azzarello JT, Saban MR, Saban R, Ashley RA, Welter JC, Fung KM, Lin HK. BMC Complement Altern Med. 2009 Mar 18;9(1):6. [Epub ahead of print] PMID: 19296830 doi:10.1186/1472-6882-9-6

Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Elmesery ME, Algayyar MM, Salem HA, Darweish MM, El-Mowafy AM. Cell Div. 2009 Apr 2;4(1):6. [Epub ahead of print] PMID: 19341447 doi:10.1186/1747-1028-4-6

Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B12. Ebbing M, Bønaa KH, Nygård O, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, Njølstad I, Refsum H, Nilsen DW, Tverdal A, Meyer K, Vollset SE. JAMA. 2009 Nov 18;302(19):2119-2126. v PMID: 19920236 Conclusion Treatment with folic acid plus vitamin B12 was associated with increased cancer outcomes and all-cause mortality in patients with ischemic heart disease in Norway, where there is no folic acid fortification of foods.

Rosmarinic acid antagonizes activator protein-1-dependent activation of cyclooxygenase-2 expression in human cancer and nonmalignant cell lines. Scheckel KA, Degner SC, Romagnolo DF. J Nutr. 2008 Nov;138(11):2098-105. PMID: 18936204

Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C Int J Cancer. 2008 Sep 15;123(6):1227-39. Review. PMID: 18623084

Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs.\nHeaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O'Connor OA.\nCancer Res. 2008 Oct 1;68(19):8031-8.\nPMID: 18829561

Cannabinoids: potential anticancer agents. Guzmán M. Nat Rev Cancer. 2003 Oct;3(10):745-55. Review. PMID: 14570037 doi:10.1038/nrc1188

Aldehyde dehydrogenase 2 and head and neck cancer: a meta-analysis implementing a Mendelian randomization approach. Boccia S, Hashibe M, Gallì P, De Feo E, Asakage T, Hashimoto T, Hiraki A, Katoh T, Nomura T, Yokoyama A, van Duijn CM, Ricciardi G, Boffetta P. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):248-54. PMID: 19124505 doi: 10.1158/1055-9965.EPI-08-0462

Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN. J Dtsch Dermatol Ges. 2008 Dec;6(12):1066-9. English, German. PMID: 19138272 DOI: 10.1111/j.1610-0387.2008.06861.x

Ayukawa F, Shibuya H, Yoshimura RI, Watanabe H, Miura M. Curative Brachytherapy for Recurrent/Residual Tongue Cancer. Strahlenther Onkol. 2007 Mar;183(3):133-137. PMID: 17340071 [PubMed - as supplied by publisher]

Schroeder CP, Yang P, Newman RA, Lotan R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther. 2004 Sep;3(9):847-52. Epub 2004 Sep 18. P

Intravenous vitamin C as a chemotherapy agent: a report on clinical cases.\nRiordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, González MJ, Mora EM, Miranda-Massari JR, Rosario N, Rivera A.\nP R Health Sci J. 2004 Jun;23(2):115-8.\nPMID: 15377059

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Ann Oncol. 2008 Nov;19(11):1969-74. Epub 2008 Jun 9. Erratum in: Ann Oncol. 2008 Dec;19(12):2095. PMID: 18544557 doi:10.1093/annonc/mdn377

Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Kandaş NO, Randolph C, Bosland MC. Nutr Cancer. 2009;61(2):251-64. PMID: 19235042

Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ. Prostate. 2008 Aug 1;68(11):1223-31. PMID: 18465755 DOI: 10.1002/pros.20788